DUBLIN, May 6, 2021 /PRNewswire/ -- Theravance
Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical
company primarily focused on the discovery, development and
commercialization of organ-selective medicines, will participate in
an investor event as follows:
- Rick E Winningham (Chief Executive Officer) will be presenting
at the Bank of America 2021 Healthcare Conference on Thursday, May 13 at 2:45
p.m. ET (11:45 a.m.
PT/7:45 p.m. IST)
Webcast of the event may be accessed by visiting Theravance.com,
under the Investors section, Presentations and Events. Replay of
the webcast will be archived on the Company's website for at least
30 days.
About Theravance Biopharma
Theravance Biopharma, Inc. is a diversified biopharmaceutical
company primarily focused on the discovery, development and
commercialization of organ-selective medicines. Our purpose is to
create transformational medicines to improve the lives of patients
suffering from serious illnesses. Our research is focused in the
areas of inflammation and immunology.
In pursuit of our purpose, we apply insights and innovation at
each stage of our business and utilize our internal capabilities
and those of partners around the world. We apply organ-selective
expertise to biologically compelling targets to discover and
develop medicines designed to treat underserved localized diseases
and to limit systemic exposure, in order to maximize patient
benefit and minimize risk. These efforts leverage years of
experience in developing lung-selective medicines to treat
respiratory disease, including FDA-approved YUPELRI® (revefenacin)
inhalation solution indicated for the maintenance treatment of
patients with chronic obstructive pulmonary disease (COPD). Our
pipeline of internally discovered programs is targeted to address
significant patient needs.
We have an economic interest in potential future payments from
Glaxo Group Limited or one of its affiliates (GSK) pursuant to its
agreements with Innoviva, Inc. relating to certain programs,
including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and
the Cross/Star logo are registered trademarks of the Theravance
Biopharma group of companies (in the U.S. and certain other
countries). YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris company. Trademarks, trade names or
service marks of other companies appearing on this press release
are the property of their respective owners.
Contact Information:
Gail Cohen
Corporate Communications
917-214-6603
investor.relations@theravance.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301285188.html
SOURCE Theravance Biopharma, Inc.